BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Friday, April 3, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Jan. 21, 2014
View Archived Issues
Safety issues noted in phase I study of cabazitaxel in gastric adenocarcinoma
Read More
The Vanderbilt University patents novel mGlu5 receptor modulators
Read More
Lanreotide autogel/depot reduces carcinoid syndrome rescue therapy in ELECT trial
Read More
Simtuzumab well tolerated in phase I and II trials
Read More
Nektar Therapeutics reviews product development status for 2014
Read More
Preliminary trial results provided for selinexor in colorectal cancer
Read More
Hybrigenics achieves first milestone under USP collaboration
Read More
Novel antibodies for cancer presented by Regeneron Pharmaceuticals
Read More
4SC Discovery discloses new casein kinase inhibitors
Read More
French and Danish researchers patent new K(Ca)3.1 channel blockers
Read More
Cystadane approved in Japan for homocystinuria
Read More
A team in Israel divulges new anti-fibrinolytic compositions for coagulation
Read More
Roche and Genentech synthesize new pim kinase inhibitors
Read More
Amarin to appeal FDA's rescindment of ANCHOR SPA agreement
Read More
Novartis synthesizes new agents for macular degeneration and other disorders
Read More
Phase I study begins for hemophilia candidate ALN-AT3SC
Read More
Pluristem's phase I/II trial of PLX-PAD cells in muscle injury meets primary endpoints
Read More
New radioligands tested for assessment of AD in living subjects
Read More
GSK launches phase I trial of GSK-2879552 in relapsed/refractory SCLC
Read More
First trials in phase III bitopertin program miss primary endpoints
Read More
Novartis opens phase II study of VAY-736 in multiple sclerosis
Read More
Eculizumab receives FDA orphan drug designation for delayed graft function in renal transplantation
Read More
French authorities grant temporary authorization for use of Raxone in LHON
Read More
